-
Mashup Score: 1The Multiple Myeloma Daily - 1 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatments for #MultipleMyeloma in the Upfront & #Relapsed Settings: https://t.co/dBKzg5WHaR #MedTwitter #Oncology #HemOnc #BloodCancer https://t.co/uDTwpPKmB2
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatments for #MultipleMyeloma in the Upfront & #Relapsed Settings: https://t.co/dBKzg5WHaR #MedTwitter #Oncology #HemOnc #BloodCancer https://t.co/VhpCFzNET6
-
-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatments for #MultipleMyeloma in the Upfront & #Relapsed Settings: https://t.co/dBKzg5WHaR #MedTwitter #Oncology #HemOnc #BloodCancer https://t.co/eiTyAx2QNb
-
-
Mashup Score: 0EPd Triplet Therapy Boosts Survival in R/R MM Vs. Pd | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination October 27, 2022 Treatment with elotuzumab plus pomalidomide/dexamethasone (EPd) resulted in a significant reduction in the risk of death compared with pomalidomide/dexamethasone (Pd) in patients with relapsed…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Treatment with elotuzumab plus pomalidomide/dexamethasone significantly reduced the risk of death in patients with #relapsed or #refractory #MultipleMyeloma who had previously received lenalidomide and a proteasome inhibitor https://t.co/ux6AxaSrqv
-
-
Mashup Score: 0Second-Line Axi-Cel Is Cost-Effective in Relapsed/Refractory DLBCL | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Skip Nav Destination September 26, 2022 Second-line axicabtagene ciloleucel (axi-cel) is cost-effective in cases of primary refractory or early relapsed and transplant-eligible diffuse large B-cell lymphoma (DLBCL), but the cost-effectiveness of…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Second-line #AxiCel was found to be cost-effective in cases of primary #refractory or early #relapsed and #transplant-eligible #DLBCL, but its cost-effectiveness in the second-line setting depends on long-term outcomes https://t.co/qr7Hb7SGf0
-
-
Mashup Score: 1
Dr. Joshua Richter, a myeloma specialist, explains what it means to have relapsed myeloma or refractory myeloma.
Source: Patient Empowerment NetworkCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @power4patients: .@JoshuaRichterMD from @MountSinaiNYC defines #relapsed and #refractory #myeloma. #mmsm https://t.co/AigU5TOKpy https:/…
-
-
Mashup Score: 1Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine — Teclistamab in Relapsed or Refractory Multiple Myeloma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
#Teclistamab in #Relapsed or Refractory #MultipleMyeloma 👇 A nice addition to existing therapies! 👉https://t.co/6OTuSXt4uf @CHUnantes🇫🇷| @Szusmani @DoctorAKrishnan #CD3 https://t.co/iEXvVXQvmf
-
-
Mashup Score: 0Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASCO Rewind: Longer follow-up demonstrated the antitumor activity of subcutaneous #epcoritamab, which induced durable, clinically meaningful responses among #relapsed/refractory B-cell #non-Hodgkinlymphoma patients: https://t.co/7wc32DPy6U #hem/onc https://t.co/e8SGSXNe45
-
-
Mashup Score: 1
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy #CheckpointBlockade #HodgkinLymphoma #Relapsed #Sensitization #Immunotherapy https://t.co/YrOiP00QLC https://t.co/6aGJeTXtri
-
The latest The Multiple Myeloma Daily! https://t.co/xnce48BDGI Thanks to @OncologyTimes #multiplemyeloma #relapsed